Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 318-324

  Hao, Yubin ^a,b   Zhao, Yuan ^a   Zhao, Xiaoyun ^b   He, Chunnian ^b   Pang, Xiaowu ^a   Wu, T C ^c,d   Califano, Joseph A ^e   Gu, Xinbin ^a,f  

^a HOWARD UNIVERSITY   (United States)

^b HEBEI GENERAL HOSPITAL   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f HOWARD UNIVERSITY CANCER CENTER   (United States)

Author keywords

Antiangiogenesis inhibitors; Bevacizumab; Non small cell lung cancer

Indexed keywords

CYCLOOXYGENASE 2; MICRORNA 141; MICRORNA 21; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; XENOGRAFT;

AGE FACTORS; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 79953795978     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.554477     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010
2. Eastham JA,May RA,Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998;90:756-760. (Pubitemid 28259187)
3. DeMarzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, NelsonWG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-269. (Pubitemid 46486616)
4. Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, Punnen S, Venkateswaran V, Toi A, Loblaw DA, Sugar L, Siminovitch KA, Narod SA. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res. 2009;15:1787-1793.
5. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89, 134-138. (Pubitemid 27034789)
6. Vilanova JC, Comet J, Barcelo-Vidal C, Barcelo J, Lopez-Bonet E, Maroto A, Arzoz M, Moreno A, real, J. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Radiology. 2009;253:135-143.
7. Gu R, Zhou C, Ma Q. Correlation between EPS composition and elevated serumPSA in prostatitis patients. ZhonghuaNan Ke Xue. 2004;10: 423-425.
8. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-864. (Pubitemid 33032105)
9. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-862. (Pubitemid 33032104)
10. He L,Hannon GJ.MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-531.
11. VellaMC, Choi EY, Lin SY, Reinert K, Slack FJ.TheC. elegansmicroRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3'UTR. Genes Dev 2004;18:132-137. (Pubitemid 38141781)
12. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004;18:504-511. (Pubitemid 38372808)
13. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-11760. (Pubitemid 39095368)
14. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-6135. (Pubitemid 47037493)
15. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45.
16. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A,Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070. (Pubitemid 41161233)
17. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-2468. (Pubitemid 46548930)
18. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res 2009;69:8472-8481.
19. Rosenfeld N, Aharonov R,Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469. (Pubitemid 351501813)
20. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci USA 2007;104:15144-15149. (Pubitemid 47619608)
21. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M,Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, AlderH, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targetingBCL2. Proc Natl Acad SciU S A 2005;102:13944-13949. (Pubitemid 41377683)
22. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY.MicroRNA-34b andMicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007;67:8433-8438. (Pubitemid 47437414)
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-10518.
24. Yan LX,Huang XF, Shao Q,Huang MY,Deng L,WuQL, Zeng YX, Shao JY.MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-2360.
25. SeikeM, GotoA, OkanoT, Bowman ED, Schetter AJ,Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, GemmaA,Kudoh S, Croce CM, Harris CC. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009;106:12085-12090.
26. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007;282:1479-1486. (Pubitemid 47076526)
27. Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, Zhou Y, Pang X, Southerland WM, Califano JA, Gu X. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res 2010;3:787-796.
28. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-1181. (Pubitemid 41417894)
29. WangWD, ChenZT,LiDZ, CaoZH, SunSL, PuP, ChenXP.Correlation between DNA repair capacity in lymphocytes and acute side effects to skin during radiotherapy in nasopharyngeal cancer patients. Clin Cancer Res 2005;11:5140-5145. (Pubitemid 41003698)
30. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004;61:60-72. (Pubitemid 39095695)
31. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 1997;89:66-71. (Pubitemid 26428079)
32. Szafranska AE, Doleshal M, Edmunds HS, Gordon., S., Luttges J, Munding JB, Barth RJ, Jr., Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716-1724.
33. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, egnasubramanian, S., Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009;69:7165-7169.
34. Yamamichi N, Shimomura R, Inada K, Sakurai K, Haraguchi T, Ozaki Y, Fujita S, Mizutani T, Furukawa C, Fujishiro M, Ichinose M, Shiogama K, Tsutsumi Y, Omata M, Iba H. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009;15:4009-4016.
35. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood 2009;114:404-414.
36. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
37. Ambs S, Prueitt RL, Yi M,Hudson RS,Howe TM, Petrocca F,Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNAexpression in prostate cancer.Cancer Res 2008, 68, 6162-6170.
38. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-2698. (Pubitemid 34462754)